Paolo Pozzilli has received his Degree in Medicine and specialized in Endocrinology & Metabolic Diseases from University “Sapienza” of Rome, Italy. Since then he has worked mainly in the field of diabetes with particular focus into type 1 diabetes (T1D) pathogenesis and prevention in collaboration with several investigators around the world for more than 30 years. He is an internationally recognized leader in this field including studies on the etiology, pathogenesis and novel forms of therapeutic intervention (immunotherapy) of T1D. He is one of the few scientists clinicians in the world who has investigated complex mechanisms of T1D development in different ethnic populations. He set up with others the EURODIAB study on the incidence of childhood T1D that is the most comprehensive mapping of the incidence of type 1 diabetes in Europe. He was the founder of the IMDIAB group (immunotherapy of T1D) in the late 1980s. He is currently a regional P.I. for TRIGR (the longest and still running trial for the primary prevention of T1D in genetically susceptible 1st degree relatives of T1D probands). In the nineties with the introduction of genetic studies applied to T1D, he was actively involved in the characterization of HLA and other gene markers in different T1D populations worldwide.
He pioneered studies focusing on the link between genetic and immunological markers with clinical findings in different populations and in relation with the residual beta cell function. He was among the first to investigate the epidemiological and pathogenetic mechanisms of latent autoimmune diabetes in adults (LADA) in Caucasian and Asian populations. His collaborations with investigators in Europe, US and more recently in China, have allowed him to implement research programmes for the identification of common T1D pathogenetic mechanisms leading to beta cell destruction. He was able to establish the first joint PhD programme in diabetes including four Universities (Barts and The London, UK; University of Ulm, Germany; University of Barcelona, Spain and University Campus Bio-Medico, Rome, Italy: The most relevant international studies in which he acted as Leader or regional P.I. include ENDIT, TRIGR, Action LADA and 13 IMDIAB trials as P.I.
He has served as consultant on T1D to countries including Middle East (UAE, Egypt), Europe (Belgium, Finland, Spain, Poland, Sweden) and has been on the scientific review committee of JDRF (USA) in different periods for a total of nearly 10 years.
He has also served for the EU in the grant selection for the 5th Framework Programme and is currently the Editor of Diabetes Metabolism Research & Reviews. Professor Pozzilli has received several awards , the most significant ones include the Andrew Cudworth Memorial Award by the British Diabetic Association, the Morgagni Award for Best Young Investigators, the Celso Prize by the Italian Society of Diabetology, the Marie Kugel Award by the Juvenile Diabetes Foundation (USA), the Diabetes Honoris Causa by the Paulescu Foundation, Romanian Diabetes Society. He has published a total of 427 peer reviewed articles (Pubmed).